Introduction. Non-alcoholic (metabolic dysfunction-associated) fatty liver disease (NAFLD) encompasses a spectrum of common pathological conditions associated with systemic metabolic dysfunction. T...
<p><strong>Tác giả:</strong> Artur V. Sauts, Приходько Вероника Александровна, I. A. Titovich, Sergey V. Okovityi</p>
<p>Introduction. Non-alcoholic (metabolic dysfunction-associated) fatty liver disease (NAFLD) encompasses a spectrum of common pathological conditions associated with systemic metabolic dysfunction. The development of new effective and safe pharmacological therapies for NAFLD and its comorbid conditions remains an ongoing challenge. The malonic acid derivative maloben (sodium 4,4’-(propanediamido)dibenzoate) is currently undergoing phase II clinical trials for NAFLD; however, its molecular mecha...</p>
<p>📄 DOI: <a href="https://doi.org/https://doi.org/10.33380/2305-2066-2026-15-4-2370" target="_blank" rel="noopener">https://doi.org/10.33380/2305-2066-2026-15-4-2370</a></p>
<p>📖 <a href="https://doi.org/https://doi.org/10.33380/2305-2066-2026-15-4-2370" target="_blank" rel="noopener">Xem bài báo đầy đủ</a></p>
Bài viết được biên soạn lại bởi LIFVietnam. Nguồn tham khảo: OpenAlex
